



Vitae Pharmaceuticals to Present at Upcoming Meetings

FORT WASHINGTON, PA, May 6, 2015 – Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, announced that it will be presenting new data on several of its product candidates for the treatment of autoimmune diseases, atopic dermatitis and acute coronary syndrome at upcoming scientific meetings.

IMMUNOLOGY 2015: The American Association of Immunologists Annual Meeting New Orleans, LA, May 8-12, 2015

Vitae will present a poster titled, “The potent, selective ROR γ t blocker, VTP-43742, suppresses Th17 production in vivo and provides greater benefit than IL-17 blockade in the EAE model of autoimmunity.” VTP-43742 is Vitae’s novel, potential first-in-class ROR γ t inhibitor being developed for autoimmune disorders.

Date: Saturday, May 9, 2015

Time: 2:30-3:45 p.m. CDT

Location: Ernest N. Morial Convention Center, Exhibit / Poster Hall

In addition, Gerard McGeehan, Ph.D., Vice President, Biology at Vitae will deliver an oral podium presentation titled “VTP-43742 is a potent and selective ROR γ t blocker that demonstrates oral efficacy in a mouse model of autoimmunity through suppression of IL-17A production.”

Date: Sunday, May 10

Time: 4:15-4:30 p.m. CDT

Location: Ernest N. Morial Convention Center, Room R08

The same data will be presented in a poster session.

Date: Monday, May 11, 2015

Time: 2:30-3:45 p.m. CDT

Location: Ernest N. Morial Convention Center, Exhibit / Poster Hall

For more information on IMMUNOLOGY 2015, visit <http://immunology2015.org/>.

**2015 Society for Investigative Dermatology Annual Meeting
Atlanta, GA, May 6-9, 2015**

Vitae will present a poster titled “The LXR ligand VTP-38543 represents a new class of therapeutic agents for the treatment of atopic dermatitis.” VTP-38543 is Vitae’s novel, potential first-in-class LXR ligand being developed for atopic dermatitis.

Date: Saturday, May 9, 2015

Time: 10 a.m.-12 p.m. EDT

Location: Hilton Atlanta, Galleria Exhibit Hall

For more information on the Society for Investigative Dermatology Annual Meeting, visit <http://www.sidnet.org/2015annualmeeting>.

**Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015
Scientific Sessions
San Francisco, CA, May 7-9, 2015**

Vitae will present a poster titled “The LXR β Selective Agonist, VTP-38443, Significantly Decreases Plaque Cholesterol Ester Content and Inflammation in a Murine Model of Accelerated Atherosclerosis.” VTP-38443 is Vitae’s novel, potential first-in-class LXR β partial agonist being developed for acute coronary syndrome.

Date: Friday, May 8, 2015

Time: 5:30-7:30 p.m. PDT

Location: Hilton San Francisco Union Square, Grand Ballroom A

For more information on the Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions, visit

http://my.americanheart.org/professional/Sessions/ATVBPVD/ATVBPVD-Scientific-Sessions_UCM_316902_SubHomePage.jsp.

About Vitae

Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs, including disclosed programs in diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis and acute coronary syndrome. This robust and growing portfolio of

novel product candidates is generated by Contour®, Vitae's proprietary structure-based drug discovery platform.

For additional information, please visit the company's website at www.vitaepharma.com.

###

INVESTORS:

Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

MEDIA:

6 Degrees PR
Tony Plohoros
(908) 940-0135
tplohoros@6degreespr.com